LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays

By LabMedica International staff writers
Posted on 04 Apr 2025
Image: The Procollagen-III-peptide (PIIINP) ELISA kit (Photo courtesy of Cisbio Bioassays)
Image: The Procollagen-III-peptide (PIIINP) ELISA kit (Photo courtesy of Cisbio Bioassays)

Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the global life sciences and diagnostics company, Revvity Inc. (Waltham, MA, USA). The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits.

The asset purchase relates to the following ELISA kits - CGA-ELISA-NG (Chromogranin A New Gen. ELISA) – CE IVD that aids diagnosis by determining the presence and progression of neuroendocrine tumor, in adults; P3NP-ELISA (N-Terminal Procollagen III Peptide ELISA) – CE IVD that measures the levels of PIIINP in serum, EDTA or Heparin plasma to assess collagen III synthesis and monitor the risk of liver fibrosis in psoriasis patients receiving methotrexate; and CGA-EL-US-NG RUO and P3NP-EL-US RUO which are research use only products for supporting further scientific advancements in research activities.

To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits. IBL has a proven track record of delivering reliable and precise specialty diagnostic tools, including high-quality IVD products. Upon completion of the asset transfer, IBL will assume full responsibility for the manufacturing, distribution and regulatory compliance of the kits. Bringing these products into the Tecan Group will ensure their continued availability to users while upholding the highest quality and regulatory standards.

“This strategic purchase aligns with our commitment to supporting customers with high-quality solutions while strengthening our portfolio in specialty diagnostics," said Mukta Acharya, Head of Tecan’s Life Sciences Business. "As regulatory requirements continue to evolve, we are proactively expanding our offering to ensure laboratories have access to reliable, compliant solutions that meet their needs today and in the future. Tecan and Cisbio have a long-standing collaboration in the IVD sector. The transition of these important ELISA kits marks a strategic step to expand the IBL specialty diagnostics portfolio under IVDR.”

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more